Related Experiment Video
Updated: Jun 3, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Moses Owoicho Abah1,2, Deborah Oganya Ogenyi1, Angelina V Zhilenkova1
1World-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Abstract:
A thorough study of Clear Cell Renal Cell Carcinoma (ccRCC) shows that combining tyrosine kinase inhibitors (TKI) with immune checkpoint inhibitors (ICI) shows promising results in addressing the tumor-promoting influences of abnormal immunological and molecular biomarkers in metastatic Clear Cell Renal Cell Carcinoma (ccRCC). These abnormal biomarkers enhance drug resistance, support tumor growth, and trigger cancer-related genes. Ongoing clinical trials are testing new treatment options that appear more effective than earlier ones. However, more research is needed to confirm their long-term safety use and potential side effects. This study highlights vital molecular and immunological biomarkers associated with drug resistance in Clear Cell Renal Cell Carcinoma (ccRCC). Furthermore, this study identifies a number of promising drug candidates and biomarkers that serve as significant contributors to the enhancement of the overall survival of ccRCC patients. Consequently, this article offers pertinent insights on both recently completed and ongoing clinical trials, recommending further toxicity study for the prolonged use of this treatment strategy for patients with metastatic ccRCC, while equipping researchers with invaluable information for the progression of current treatment strategies.
Insights
Combining tyrosine kinase inhibitors (TKI) with immune checkpoint inhibitors (ICI) shows promise for metastatic Clear Cell Renal Cell Carcinoma (ccRCC). Further research is needed to confirm long-term safety and side effects of these advanced cancer treatments.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Metastatic Clear Cell Renal Cell Carcinoma (ccRCC) is often driven by abnormal molecular and immunological biomarkers.
- These biomarkers contribute to tumor growth, promote drug resistance, and activate cancer-related genes.
Purpose of the Study:
- To investigate the efficacy of combining tyrosine kinase inhibitors (TKI) with immune checkpoint inhibitors (ICI) in metastatic ccRCC.
- To identify key molecular and immunological biomarkers associated with drug resistance and patient survival in ccRCC.
Main Methods:
- Review of current literature and ongoing clinical trials for ccRCC treatment.
- Analysis of molecular and immunological biomarkers implicated in ccRCC progression and treatment response.
Main Results:
- Combination therapy of TKI and ICI demonstrates promising results in overcoming tumor-promoting biomarker influences.
- Identification of specific biomarkers that correlate with improved overall survival in ccRCC patients.
- Several promising drug candidates and biomarkers have been identified.
Conclusions:
- Combination TKI and ICI therapy is a promising strategy for metastatic ccRCC.
- Further investigation into the long-term safety and potential side effects of this treatment is recommended.
- The study provides valuable insights for advancing ccRCC treatment strategies and identifies key biomarkers for future research.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy